E-viri
Recenzirano
-
Cortés, Javier; Kim, Sung-Bae; Chung, Wei-Pang; Im, Seock-Ah; Park, Yeon Hee; Hegg, Roberto; Kim, Min Hwan; Tseng, Ling-Ming; Petry, Vanessa; Chung, Chi-Feng; Iwata, Hiroji; Hamilton, Erika; Curigliano, Giuseppe; Xu, Binghe; Huang, Chiun-Sheng; Kim, Jee Hyun; Chiu, Joanne W.Y; Pedrini, Jose Luiz; Lee, Caleb; Liu, Yali; Cathcart, Jillian; Bako, Emarjola; Verma, Sunil; Hurvitz, Sara A
The New England journal of medicine, 03/2022, Letnik: 386, Številka: 12Journal Article
In patients with metastatic HER2-positive breast cancer that had progressed after primary therapy, treatment with the antibody–drug conjugate trastuzumab deruxtecan resulted in a higher response rate and longer progression-free survival than trastuzumab emtansine. Since trastuzumab deruxtecan was associated with interstitial pulmonary fibrosis, close monitoring of pulmonary function is warranted.
